MRSA Nasal Decolonization License Received from Health Canada



    Ondine Introduces Non-Antibiotic Alternative for Prevention of Superbug
    Transmission

    VANCOUVER, March 19 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP) today announced that it has received a Health Canada license for
expanded use of the Periowave(TM) photodisinfection system. The new indication
is for decolonization of pathogenic bacteria such as methicillin-resistant
Staphyloccocus aureus (MRSA) in the nose.
    "Approval of our new photodisinfection system for nasal pathogens is a
significant milestone, as it enables us to introduce cost-effective solutions
that have the potential to decrease the rate of nosocomial (hospital)
infection, while avoiding development of antibiotic resistance", said Carolyn
Cross, President and CEO of Ondine Biopharma. "Ondine intends to proceed with
post-marketing trials in hospital settings in British Columbia throughout the
balance of the year, and expects first revenues from this indication in the
second half of 2008. We are truly excited to expand the use of this effective,
painless and fast-acting technology into the medical and hospital markets."

    About MRSA and Antibiotic Resistance

    The MRSA 'superbug' has become resistant to most antibiotics.
Approximately 95% of all patients with an MRSA infection do not respond to
first-line antibiotics. If the bacterium enters the bloodstream, nearly half
of these critically ill patients will die despite access to potent
antibiotics. Healthy people (including hospital healthcare workers) carry MRSA
bacteria in their noses and on the skin, and inadvertently pass it on to
others or self-infect by sneezing, breathing, or by touch-based transfer. More
than 2 million hospital acquired infections occur each year in the U.S.
    Antibiotic resistance is becoming a growing concern; it is crucial that
new non-antibiotic modalities to fight bacterial infections are developed.
According to a Centers for Disease Control (CDC) report, antibiotic resistance
is 'one of the world's most pressing public health problems.' Over the last
decade, almost every class of bacteria has become less responsive to
antibiotics and the burden on the healthcare system related to treating
antibiotic resistant infections exceeds $8 billion in both the U.S. and U.K.

    About Periowave(TM) and Photodisinfection (PDD)

    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
compounds to specifically target and destroy microbial pathogens and reduce
the symptoms of disease. The compounds are generally topically applied and one
or more lasers are used to activate the compounds and complete the
disinfection. The Photodisinfection technologies were developed by Professor
Michael Wilson and colleagues at the Eastman Dental Institute, University
College London, and licensed to Ondine by UCL Business PLC, University College
London. Additional information about Periowave(TM) is available at
www.periowave.com.

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading-edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance.
    The Company is headquartered in Vancouver, British Columbia, Canada, with
a research laboratory in Redmond, Washington, USA, a sales and marketing
subsidiary in York, Pennsylvania, and an international office in St Michael,
Barbados. For additional information, please visit the Company's website at:
www.ondinebiopharma.com.

    Forward-Looking Statements:
    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.





For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com

Organization Profile

ONDINE BIOPHARMA CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890